Sanofi takes a bold step by acquiring Blueprint MedicinesSanofi Makes Bold Move with $9.5 Billion Acquisition of Blueprint Medicines
By Ion Jauregui – Analyst at ActivTrades
French pharmaceutical giant Sanofi (EPA:SAN) has kicked off 2025 with a bold strategic move: the acquisition of U.S.-based biotech Blueprint Medicines (NASDAQ:BPMC) for up to $9.5 b
Key facts today
Sanofi must pay 150.7 million euros to France's health insurance for anti-competitive practices linked to Plavix. This follows a 40.6 million euro fine from 2013.
3.4 EUR
5.81 B EUR
42.93 B EUR
2.43 B
About Sanofi SA
Sector
Industry
CEO
Paul Hudson
Website
Headquarters
Paris
Founded
1994
ISIN
US80105N1054
FIGI
BBG000FDBVQ5
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.
Related stocks
Short on SANOFI (SAN)Short until 87.0 (support zone).
Strong selling pressure confirmed by two large red candles.
Recent green candle shows buyer hesitation (small body, upper wick).
No significant volume to support a bullish rebound.
RSI remains weak but needs surveillance.
Rebound lacking conviction.
Sanofi (SNY): A Strong Investment CaseCompany Overview:
Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion.
Investment Highlights:
Dividend Yield: 3.8%, more than double the S&P 500 average.
Drug Portfolio: Diverse and includes successful drug developments.
Pipeline: Prom
Is Sanofi Undervalue by 22% ?I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US801060AD6
Sanofi SA 3.625% 19-JUN-2028Yield to maturity
3.90%
Maturity date
Jun 19, 2028
FR1332437
Sanofi SA 1.875% 21-MAR-2038Yield to maturity
3.56%
Maturity date
Mar 21, 2038
FR1340985
Sanofi 1.25% 21-MAR-2034Yield to maturity
3.28%
Maturity date
Mar 21, 2034
FR14010MR
Sanofi SA 3.0% 23-JUN-2032Yield to maturity
3.07%
Maturity date
Jun 23, 2032
FR1400Y1I
Sanofi SA 2.75% 11-MAR-2031Yield to maturity
2.93%
Maturity date
Mar 11, 2031
FR1350511
Sanofi 1.5% 01-APR-2030Yield to maturity
2.77%
Maturity date
Apr 1, 2030
FR1332435
Sanofi SA 1.375% 21-MAR-2030Yield to maturity
2.77%
Maturity date
Mar 21, 2030
FR1340984
Sanofi 0.875% 21-MAR-2029Yield to maturity
2.66%
Maturity date
Mar 21, 2029
FR14010MQ
Sanofi SA 2.625% 23-JUN-2029Yield to maturity
2.61%
Maturity date
Jun 23, 2029
FR1314400
Sanofi 1.125% 05-APR-2028Yield to maturity
2.39%
Maturity date
Apr 5, 2028
FR1320163
Sanofi 0.5% 13-JAN-2027Yield to maturity
2.22%
Maturity date
Jan 13, 2027
See all SNW2 bonds
Curated watchlists where SNW2 is featured.